498 A Multi-Centre Proof of Concept Study to Assess Efficacy and Safety of a New Liquid Endoscopic Hemostatic Agent (Seraseal / Fastact ®) in Patients With Active Gastrointestinal Bleeding

Introduction: Endoscopic treatment of severe gastrointestinal bleeding can be difficult and high technical expertise is required. A simple and effective method of endoscopic hemostasis would have a significant impact on the treatment of active gastrointestinal bleeding. Aim of the study is to assess the efficacy and safety of endoscopic hemostasis with liquid combined activated factors IIa, VIIa, IXa, Xa (SerasealTM/Fastact, Wortham Laboratories, Chattanooga, TN, USA).